ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study

BACKGROUND: Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) is an unmet need. ADS-5102 (amantadine) extended-release capsules is being developed for the treatment of LID in patients with PD. OBJECTIVE: Evaluate the long-term safety and tolerability of 274 mg ADS-51...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Pahwa, Rajesh, Tanner, Caroline M., Oertel, Wolfgang, Isaacson, Stuart H., Johnson, Reed, Felt, Larissa, Stempien, Mary Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611804/
https://www.ncbi.nlm.nih.gov/pubmed/28777755
http://dx.doi.org/10.3233/JPD-171134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611804/
https://www.ncbi.nlm.nih.gov/pubmed/28777755
http://dx.doi.org/10.3233/JPD-171134

Ejemplares similares